A progressive loss of ERβ expression during the process of carcinogenesis has been documented in prostate [25] and breast [26] cancers, suggesting a role for ERβ as a potential inhibitor of cellular proliferation and/or transformation [27]. This evidence concerns the gene ESR2 and cancer.